Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM (NCT04195139)
A Randomised Phase II Study of NivolUmab and TeMozolomide vs Temozolomide Alone in Newly Diagnosed Elderly Patients With Glioblastoma (NUTMEG)
🩺 Plain-English Summary (8th-Grade Level)
This study aims to investigate effect of Nivolumab and Temozolomide vs Temozolomide alone on overall survival in newly diagnosed elderly patients with glioblastoma. Who is it for? You may be eligible to join this study if you are aged 65 years or above, with newly diagnosed histologically confirmed GBM (WHO grade IV glioma including gliosarcoma) following surgery. The study aims to evaluate whether the combination of adjuvant nivolumab with temozolomide improves overall survival outcomes for this patient population. The outcome of the study will help determine the most effective treatment for patients with glioblastoma in the future.
Who can join: Review the eligibility criteria below.
Location: Duke University Medical Center — Durham, North Carolina
Age range: 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- Duke University Medical Center — Durham, North Carolina
- Campbelltown Hospital — Campbelltown, New South Wales
- Chris O'Brien Lifehouse — Camperdown, New South Wales
- Gosford Hospital — Gosford, New South Wales
- Newcastle Private Hospital — New Lambton Heights, New South Wales
- Port Macquarie Hospital — Port Macquarie, New South Wales
- Prince of Wales Hospital — Randwick, New South Wales
- Royal North Shore Hospital — Saint Leonards, New South Wales
- Wollongong Hospital — Wollongong, New South Wales
- Royal Brisbane and Women's Hospital — Herston, Queensland
- Icon Cancer Centre — South Brisbane, Queensland
- Princess Alexandra Hospital — Woolloongabba, Queensland
- Royal Adelaide Hospital — Adelaide, South Australia
- Flinders Medical Centre — Bedford Park, South Australia
- Royal Hobart Hospital — Hobart, Tasmania
- Monash Medical Centre — Clayton, Victoria
- Austin Hospital — Heidelberg, Victoria
- Peter MacCallum Cancer Centre — Melbourne, Victoria
- Epworth Healthcare — Richmond, Victoria
- Sir Charles Gairdner Hospital — Nedlands, Western Australia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Glioblastoma Multiforme
- A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme — Iowa City, Iowa
- Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM) — Baltimore, Maryland
- Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme — Washington D.C., District of Columbia
- A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM — Tucson, Arizona
- Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients — Phoenix, Arizona
- Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM — Stanford, California
Explore by condition: All Glioblastoma Multiforme clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.